End-of-Life Care  

 

• General practitioners’ perspectives on the avoidability of hospitalizations at the end of life: A mixed-method study.De Korte-Verhoef MC, Pasman HR, Schweitzer BP, Francke AL, Onwuteaka-Philipsen BD, Deliens L.Palliat Med. 2014 Apr 2
• Burden for family carers at the end of life; a mixed-method study of the perspectives of family carers and GPs.De Korte-Verhoef MC, Pasman HR, Schweitzer BP, Francke AL, Onwuteaka-Philipsen BD, Deliens L.BMC Palliat Care. 2014 Mar 31;13(1):16.
• Bridging the Gap Between Continuous Sedation Until Death and Physician-Assisted Death: A Focus Group Study in Nursing Homes in Flanders, Belgium.Rys S, Deschepper R, Mortier F, Deliens L, Bilsen J.Am J Hosp Palliat Care. 2014 Mar 26.
• Seizures in patients with high-grade glioma: a serious challenge in the end-of-life phase.Sizoo EM, Koekkoek JA, Postma TJ, Heimans JJ, Pasman HR, Deliens L, Taphoorn MJ, Reijneveld JC.BMJ Support Palliat Care. 2014 Mar;4(1):77-80
• End-of-life medical treatment preference discussions and surrogate decision-maker appointments: evidence from Italy, Spain, belgium and the Netherlands.Evans N, Pasman HR, Vega Alonso T, Van den Block L, Miccinesi G, Van Casteren V, Donker G, Bertolissi S, Zurriaga O, Deliens L, Onwuteaka-Philipsen B; EUROIMPACT.BMJ Support Palliat Care. 2013 Jun;3(2):235
• End-of-life care in general practice: A cross-sectional, retrospective survey of ‘cancer’, ‘organ failure’ and ‘old-age/dementia’ patients.Evans N, Pasman HR, Donker GA, Deliens L, Van den Block L, Onwuteaka-Philipsen B; on behalf of EUROIMPACT.Palliat Med. 2014 Mar 18. [Epub ahead of print]
• Burden on family carers and care-related financial strain at the end of life: a cross-national population-based study.Pivodic L, Van den Block L, Pardon K, Miccinesi G, Vega Alonso T, Boffin N, Donker GA, Cancian M, López-Maside A, Onwuteaka-Philipsen BD, Deliens L; on behalf of EURO IMPACT.
• Re: A response to Willis et al.Anquinet L, Raus K, Sterckx S, Smets T, Deliens L, Rietjens JA.Palliat Med. 2014 Apr;28(4):369. doi: 10.1177/0269216314522319.
• Forgoing artificial nutrition or hydration at the end of life: a large cross-sectional survey in Belgium.Chambaere K, Loodts I, Deliens L, Cohen J.J Med Ethics. 2014 Mar 13. doi: 10.1136/medethics-2013-101527. [Epub ahead of print
• The acute hospital setting as a place of death and final care: A qualitative study on perspectives of family physicians, nurses and family carers.Reyniers T, Houttekier D, Cohen J, Pasman HR, Deliens L.Health Place. 2014 Feb 24;27C:77-83. doi: 10.1016/j.healthplace.2014.02.002. [Epub ahead of print]
• The effect and process evaluations of the national quality improvement programme for palliative care: the study protocol.Raijmakers NJ, Hofstede JM, de Nijs EJ, Deliens L, Francke AL.BMC Palliat Care. 2014 Feb 21;13(1):5. doi: 10.1186/1472-684X-13-5.
• Early identification of palliative care needs by family physicians: A qualitative study of barriers and facilitators from the perspective of family physicians, community nurses, and patients.Beernaert K, Deliens L, De Vleminck A, Devroey D, Pardon K, Van den Block L, Cohen J.Palliat Med. 2014 Feb 17. [Epub ahead of print]
• What justifies a hospital admission at the end of life? A focus group study on perspectives of family physicians and nurses.Reyniers T, Houttekier D, Cohen J, Pasman HR, Deliens L.Palliat Med. 2014 Feb 17. [Epub ahead of print]
• Factors Associated with Initiation of Advance Care Planning in Dementia: A Systematic Review.van der Steen JT, van Soest-Poortvliet MC, Hallie-Heierman M, Onwuteaka-Philipsen BD, Deliens L, de Boer ME, Van den Block L, van Uden N, Hertogh CM, de Vet HC.J Alzheimers Dis. 2014 Feb 14. [Epub ahead of print]
• Barriers to advance care planning in cancer, heart failure and dementia patients: a focus group study on general practitioners’ views and experiences.De Vleminck A, Pardon K, Beernaert K, Deschepper R, Houttekier D, Van Audenhove C, Deliens L, Vander Stichele R.PLoS One. 2014 Jan 21;9(1):e84905. doi: 10.1371/journal.pone.0084905. eCollection 2014 Jan 21.
• Effectiveness of the ‘availability, current issues and anticipation’ (ACA) training programme for general practice trainees on communication with palliative care patients: A controlled trial.Slort W, Blankenstein AH, Schweitzer BP, Deliens L, van der Horst HE.Patient Educ Couns. 2014 Apr;95(1):83-90. doi: 10.1016/j.pec.2013.12.012. Epub 2013 Dec 26
• Labelling of end-of-life decisions by physicians.Deyaert J, Chambaere K, Cohen J, Roelands M, Deliens L.J Med Ethics. 2014 Jan 3. doi: 10.1136/medethics-2013-101854. [Epub ahead of print]
• Palliative care service use in four European countries: a cross-national retrospective study via representative networks of general practitioners.Pivodic L, Pardon K, Van den Block L, Van Casteren V, Miccinesi G, Donker GA, Alonso TV, Alonso JL, Aprile PL, Onwuteaka-Philipsen BD, Deliens L; EURO IMPACT.PLoS One. 2013 Dec 30;8(12):e84440. doi: 10.1371/journal.pone.0084440. eCollection 2013
• Dying in hospital: a study of incidence and factors related to hospital death using death certificate data.Houttekier D, Cohen J, Pepersack T, Deliens L.Eur J Public Health. 2013 Dec 23. [Epub ahead of print
• The end-of-life phase of high-grade glioma patients: a systematic review.Sizoo EM, Pasman HR, Dirven L, Marosi C, Grisold W, Stockhammer G, Egeter J, Grant R, Chang S, Heimans JJ, Deliens L, Reijneveld JC, Taphoorn MJ.Support Care Cancer. 2014 Mar;22(3):847-57. doi: 10.1007/s00520-013-2088-9. Epub 2013 Dec 14.
• Physicians’ experiences and perspectives regarding the use of continuous sedation until death for cancer patients in the context of psychological and existential suffering at the end of life. Anquinet L, Rietjens J, van der Heide A, Bruinsma S, Janssens R, Deliens L, Addington-Hall J, Smithson WH, Seymour J. Psychooncology. 2013 Dec 5.
• A Favorable Course of Palliative Sedation: Searching for Indicators Using Caregivers’ Perspectives. Brinkkemper T, Rietjens JA, Deliens L, Ribbe MW, Swart SJ, Loer SA, Zuurmond WW, Perez RS. Am J Hosp Palliat Care. 2013 Dec 2.
• Barriers and facilitators for general practitioners to engage in advance care planning: A systematic review. De Vleminck A, Houttekier D, Pardon K, Deschepper R, Van Audenhove C, Vander Stichele R, Deliens L. Scand J Prim Health Care. 2013 Dec;31(4):215-26
• When do people with dementia die peacefully? An analysis of data collected prospectively in long-term care settings. De Roo ML, van der Steen JT, Galindo Garre F, Van Den Noortgate N, Onwuteaka-Philipsen BD, Deliens L, Francke AL; on behalf of EURO IMPACT. Palliat Med. 2013 Nov 29.
• Is educational attainment related to end-of-life decision-making? A large post-mortem survey in Belgium. Chambaere K, Rietjens JA, Cohen J, Pardon K, Deschepper R, Pasman HR, Deliens L. BMC Public Health. 2013 Nov 9;13(1):1055.
• Dying in Hospital with Dementia and Pneumonia: A Nationwide Study Using Death Certificate Data. Houttekier D, Reyniers T, Deliens L, Van Den Noortgate N, Cohen J.Gerontology. 2013 Oct 25.
• Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire. Sizoo EM, Dirven L, Reijneveld JC, Postma TJ, Heimans JJ, Deliens L, Pasman HR, Taphoorn MJ. J Neurooncol. 2013 Oct 29.

 

Hematology and Immunology

• Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.PLoS One. 2013 Nov 6;8(11):e79752.
• Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.Lemaire M, D’Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, Kronenberger P, Wernery U, Muyldermans S, Devoogdt N, Vanderkerken K.Leukemia. 2014 Feb;28(2):444-7. doi: 10.1038/leu.2013.292. Epub 2013 Oct 9.
•  Vorinostat-induced bone loss might be related to drug toxicity. Xu S, De Veirman K, Vanderkerken K, Van Riet I. Bone. 2013 Dec;57(2):384-5.
• Upregulation of miR-135b Is Involved in the Impaired Osteogenic Differentiation of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients. Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. PLoS One. 2013 Nov 6;8(11):e79752.
• Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Lemaire M, D’Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, Kronenberger P, Wernery U, Muyldermans S, Devoogdt N, Vanderkerken K. Leukemia. 2013 Oct 9.
•  Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A, Racanelli V, Catacchio I, Berardi S, Basile A, Menu E, Ruggieri S, Nico B, Ribatti D, Fumarulo R, Dammacco F, Vanderkerken K, Vacca A. Leukemia. 2013 Sep 2

Laboratory of Medical and Molecular Oncology

 

• Gastrointestinal stromal tumor of the stomach: progresses in diagnosis and treatment.De Vogelaere K, Aerts M, Haentjens P, De Grève J, Delvaux G.Acta Gastroenterol Belg. 2013 Dec;76(4):403-6
• Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group.Int J Gynecol Cancer. 2014 Mar;24(3):468-77.
• Detection of EGFR-TK Domain-activating Mutations in NSCLC With Generic PCR-based Methods.Shahi RB, De Brakeleer S, De Grève J, Geers C, In’t Veld P, Teugels E.Diagn Mol Pathol. 2014 Jan 30.
• How to monitor cardiac toxicity of chemotherapy: time is muscle!Kerkhove D, Fontaine C, Droogmans S, De Greve J, Tanaka K, Van De Veire N, Van Camp G. Heart. 2013 Dec 17. doi: 10.1136/heartjnl-2013-303815
•   Performance of Two Geriatric Screening Tools in Older Patients With Cancer. Kenis C, Decoster L, Van Puyvelde K, De Grève J, Conings G, Milisen K, Flamaing J, Lobelle JP, Wildiers H. J Clin Oncol. 2013 Nov 25.
• The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. Decoster L, Kenis C, Van Puyvelde K, Flamaing J, Conings G, De Grève J, Mets T, Milisen K, Lobelle JP, Wildiers H. J Geriatr Oncol. 2013 Jul;4(3):235-41.
• The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients. De Couck M, van Brummelen D, Schallier D, De Grève J, Gidron Y. Oncol Rep. 2013 Nov;30(5):2435-41.
• Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of poly(ADP-ribose) polymerase inhibitor resistance: a multi-institutional study. Ang JE, Gourley C, Powell B, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis UA, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore M, Lord CJ, Ashworth A, Kaye SB.Clin Cancer Res. 2013 Oct 1;19(19):5485-93.
• Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).Ades F, Azambuja Ed, Daugaard G, Ameye L, Moulin C, Paesmans M, Jong DD, Decoster L, Greve JD, Ismael G, Møller AK, Piccart M, Awada A.J Chemother. 2013;25(4):239-46
• miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C, De Grève J.PLoS One. 2013;8(3):e60317
• Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.Chen G, Noor A, Kronenberger P, Teugels E, Umelo IA, De Grève J.PLoS One. 2013;8(3):e59708

 

Laboratory of Molecular and Cellular Therapy

• A Short Treatment with Galactomannan GM-CT-01 Corrects the Functions of Freshly Isolated Human Tumor-Infiltrating Lymphocytes.Demotte N, Bigirimana R, Wieërs G, Stroobant V, Squifflet JL, Carrasco J, Thielemans K, Baurain JF, Van Der Smissen P, Courtoy PJ, van der Bruggen P.Clin Cancer Res. 2014 Apr 1;20(7):1823-33. doi: 10.1158/1078-0432.CCR-13-2459
• Immunogenicity of targeted lentivectors.Goyvaerts C, Kurt de G, Van Lint S, Heirman C, Van Ginderachter JA, De Baetselier P, Raes G, Thielemans K, Breckpot K.Oncotarget. 2014 Feb 15;5(3):704-15
• Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, Thielemans K, Breckpot K.Gene Ther. 2014 Mar;21(3):262-71. doi: 10.1038/gt.2013.80.
• Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. Benteyn D, Anguille S, Van Lint S, Heirman C, Van Nuffel AM, Corthals J, Ochsenreither S, Waelput W, Van Beneden K, Breckpot K, Van Tendeloo V, Thielemans K, Bonehill A. Mol Ther Nucleic Acids. 2013 Nov 19;2:e134.
• HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption. de Goede AL, van Deutekom HW, Vrancken B, Schutten M, Allard SD, van Baalen CA, Osterhaus AD, Thielemans K, Aerts JL, Keşmir C, Lemey P, Gruters RA. AIDS. 2013 Oct 19.

Translational Radiation Oncology and Physics

• Impact of planning target volume margins and rectal distention on biochemical failure in image-guided radiotherapy of prostate cancer.Engels B, Soete G, Gevaert T, Storme G, Michielsen D, De Ridder M.Radiother Oncol. 2014 Mar 13. pii: S0167-8140(14)00103-0.
• Reply to the letter to the editor ‘Are male gender and nonadenocarcinoma histology valid prognostic factors for breast cancer?’ by Eren et al.de Vin T, Engels B, Gevaert T, Storme G, De Ridder M.Ann Oncol. 2014 Apr;25(4):911-2.
• Breast conserving treatment for breast cancer: dosimetric comparison of different non-invasive techniques for additional boost delivery.Van Parijs H, Reynders T, Heuninckx K, Verellen D, Storme G, De Ridder M.Radiat Oncol. 2014 Jan 27;9:36.
• Feasibility of using the Vero SBRT system for intracranial SRS.Burghelea M, Verellen D, Gevaert T, Depuydt T, Poels K, Simon V, De Ridder M.J Appl Clin Med Phys. 2014 Jan 6;15(1):4437.
• Advances in radiotherapy and targeted therapies for rectal cancer.Sermeus A, Leonard W, Engels B, De Ridder M.World J Gastroenterol. 2014 Jan 7;20(1):1-5.
• Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival.de Vin T, Engels B, Gevaert T, Storme G, De Ridder M.Ann Oncol. 2014 Feb;25(2):467-71.
• Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: Report on late toxicity and outcome.Engels B, Platteaux N, Van den Begin R, Gevaert T, Sermeus A, Storme G, Verellen D, De Ridder M.Radiother Oncol. 2014 Jan;110(1):155-9
• A complementary dual-modality verification for tumor tracking on a gimbaled linac system. Poels K, Depuydt T, Verellen D, Engels B, Collen C, Heinrich S, Duchateau M, Reynders T, Leysen K, Boussaer M, Steenbeke F, Tournel K, Gevaert T, Storme G, De Ridder M. Radiother Oncol. 2013 Dec;109(3):469-74.
• Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: Report on late toxicity and outcome. Engels B, Platteaux N, Van den Begin R, Gevaert T, Sermeus A, Storme G, Verellen D, De Ridder M. Radiother Oncol. 2013 Nov 12
• A complementary dual-modality verification for tumor tracking on a gimbaled linac system. Poels K, Depuydt T, Verellen D, Engels B, Collen C, Heinrich S, Duchateau M, Reynders T, Leysen K, Boussaer M, Steenbeke F, Tournel K, Gevaert T, Storme G, De Ridder M. Radiother Oncol. 2013 Dec;109(3):469-74.
• Hypoxia integration in the serological proteome analysis unmasks tumor antigens and fosters the identification of anti-phospho-eEF2 antibodies as potential cancer biomarkers. Grandjean M, Sermeus A, Branders S, Defresne F, Dieu M, Dupont P, Raes M, De Ridder M, Feron O. PLoS One. 2013 Oct 10;8(10):e76508.